久久人人爽人人爽人人片 I 欧美大片在线观看 I 亚洲精品中文字幕在线观看 I 狠狠干2019 I 伊人av影院 I 五月婷婷丁香花 I 亚洲天堂社区 I xxxx视频在线观看 I 中国一级大黄大黄大色毛片 I 久久人妻免费视频 I 91福利免费 I 欧美日韩色综合 I av日韩高清 I 国产欧美视频一区二区 I 五月天丁香婷 I 亚洲 视频 一区 I 99九九精品视频 I 免播放器在线视频 I a欧美在线 I 亚洲自拍成人 I 欧美久久综合网 I 波多野结衣国产在线 I 午夜影院404 I 97人人爽人人喊人人模波多 I 91操在线观看 I 99在线看视频 I 人人澡人人妻人人爽人人蜜桃 I 国产免费高清69式视频在线观看

Many industrial innovative products are coming soon

COVID-19 antibody detection reagent and many other products go out of China and enter the international market

Expanded R&D team and introduced new R&D technology

Realized whole-line cold chain logistics for the first time nationwide

Completed the development and started the clinical test of many industry-leading project, such as irradiator, multiple, HIV, etc.

Be recognized as provincial level innovation and industrialization demonstration enterprise for several times

Established "Guangdong Postdoctoral Innovation Practice Base"

Be approved as a national “Post-Doctoral Research Center”

Established Suzhou R&D center

Moved into the new industrial park with a floor area of 23,000 m2

Cooperated with many international IVD enterprises, such as Unipath, Fujirebro, Siemens, MP, etc.

The market share of AIDS confirmation reagents reached 80%, and the market share of drug concentration detection reached 50%,Many self-developed products occupied over 60% of the market share.Many products became reference methods for disease detection, such as MYCOII and TP.PA.

1989, the first subsidiary of Livzon Pharmaceutical Group Inc.

Obtained pharmaceutical manufacturing license

Many products were successfully developed and marketed, including HBV, HIV, HCV ELISA reagents